Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer

NCT05795296 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Stomach Neoplasms

Interventions

DRUG: Fruquintinib
DRUG: Sintilimab

Sponsor

RenJi Hospital